NCT03202303 - Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD) | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

April 12, 2019

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions

Autism Spectrum Disorder

Interventions

DRUG

Cannabidivarin

Weight-based dosing of 10 mg/kg/day of CBDV

DRUG

Matched Placebo

Weight-based dosing of 10 mg/kg/day of placebo

Trial Locations (2)

COMPLETED

New York University (NYU) Langone, New York

RECRUITING

Montefiore Medical Center, The Bronx